scholarly journals Outcome of bowel resection in women with advanced ovarian carcinoma

2016 ◽  
Author(s):  
Ajit Sebastian ◽  
Dhanya Susan Thomas ◽  
Anitha Thomas ◽  
Rachel Chandy ◽  
Abraham Peedicayil
Keyword(s):  
Surgical Site Infection ◽  
Ovarian Carcinoma ◽  
Bowel Resection ◽  
Disease Free Survival ◽  
Site Infection ◽  
Free Survival ◽  
Mortality And Morbidity ◽  
Optimal Debulking ◽  
Disease Free ◽  
Carcinoma Ovary

Aim: To evaluate the mortality and morbidity related to bowel resection in women with advanced ovarian carcinoma. Methods: Retrospective case series of 47 women with stage III and IV carcinoma ovary who underwent bowel resection, over the period of 5 years from Jan 2011 to Dec 2015. The disease free survival was assessed and the prognostic factors for disease free survival was also analysed by bivariate analysis. Results: In this cohort 64% (30/47) had primary debulking, 21% (10/47) had interval debulking and 15% (7/47) had secondary debulking. The mean period of follow up was 23 months (1 – 45 month). The mortality was 15% (7/47), while major morbidity like anastomotic leak were nil. The three variables considered for mortality were relaparotomy, paralytic ileus and surgical site infection. 6% (3/47) had relaparotomy, 21% (10/47) had paralytic iileus and 15% (7/47) had surgical site infection. The overall morbidity was 42.5% (20/47). A total 34% (16/47) of patients had stoma. 79% (37/47) patients had optimal debulking. Conclusion: Bowel resection in optimally selected cases of advanced carcinoma ovary is a good option with limited mortality and morbidity. Often, bowel resection is the only way to achieve optimal debulking.

scholarly journals Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: A pilot study

Tumor Biology ◽  
2020 ◽  
Vol 42 (5) ◽  
pp. 101042832091919 ◽  
Author(s):  
Mariana Cartaxo Alves ◽  
Fernando Luiz Affonso Fonseca ◽  
Alayne Magalhães Trindade Domingues Yamada ◽  
Lílian Arruda do Rego Barros ◽  
André Lopes ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Carcinoma ◽  
Systemic Treatment ◽  
Disease Free Survival ◽  
Advanced Ovarian Cancer ◽  
Early Response ◽  
Circulating Tumor Dna ◽  
Free Survival ◽  
Disease Free ◽  
Tumor Dna

Detection of circulating tumor DNA is a new noninvasive technique with potential roles in diagnostic, follow-up, and prognostic evaluation of patients with many types of solid tumors. We aimed to evaluate the role of circulating tumor DNA in the setting of metastatic ovarian carcinoma. A prospective cohort of patients with metastatic ovarian cancer who were referred to systemic therapy was enrolled. Blood samples were collected before the start of treatment and monthly thereafter for 6 months. Circulating tumor DNA was quantified by real-time quantitative reverse transcription polymerase chain reaction of different lengths of Arthrobacter luteus elements as described by Umetani et al. A total of 11 patients were included, 2 for primary disease and 9 for recurrent disease. After the first cycle of chemotherapy, patients whose circulating tumor DNA levels increased from baseline were more likely to respond to chemotherapy than those whose circulating tumor DNA levels did not increase (p = 0.035). Furthermore, patients whose circulating tumor DNA levels rose after the first cycle of chemotherapy also had improved disease-free survival compared to those whose circulating tumor DNA levels did not increase (p = 0.0074). We conclude that the increase in circulating tumor DNA values collected in peripheral blood after the first cycle of systemic treatment in patients with advanced ovarian cancer is associated with an early response to systemic treatment and correlates with superior disease-free survival in this population. Circulating tumor DNA might be a specific, noninvasive, and cost-effective new biomarker of early response to systemic treatment in these patients.

THE ROLE OF CYTOREDUCTIVE SURGERY (CRS) AND INTRAPERITONEAL INTRAOPERATIVE CHEMOTHERAPY (IIC) IN THE TREATMENT OF PERITONEAL CARCINOMATOSIS FROM COLORECTAL ORIGIN

2017 ◽  
pp. 53-58
Author(s):  
Y. A. Shelygin ◽  
S. I. Achkasov ◽  
O. I. Sushkov ◽  
A. A. Ponomarenko
Keyword(s):  
Disease Free Survival ◽  
Morbidity Rate ◽  
Free Survival ◽  
Strategy Method ◽  
Mortality And Morbidity ◽  
Early Results ◽  
Colorectal Origin ◽  
The Empirical Analysis ◽  
Disease Free

AIM. To assess early results and survival in patients with CRS and IIC strategy. METHOD. 56 CRC with PC patients underwent CRS+IIC. pT4 stage occurred in 38 (67,5 %) pts. N+ status was detected in 39 (69 %) cases. In 44 (79 %) pts. carcinomatosiswas synchronous. PCI was rangedfrom 1 to 21 (Me=3). RESULTS. Mortality and morbidity rate in postoperative 30 days was 0 % and 14 %, respectively. The median disease-free survival (DFS) was 21 months. Multivariate analysis revealed that PCI (p=0,0007) and the presence of extraperitoneal metastases (p=0,0097) were independent negative predictors of DFS. The empirical analysis showed that level of PCI more than 8 was the predictor of negative prognosis (p=0,044). CONCLUSION. It has been shown that poor prognosis factors were PCI more than 8, and the presence of distant extraperitoneal metastases of CRC.

The Grading of Lymphovascular Space Invasion in Epithelial Ovarian Carcinoma

2010 ◽  
Vol 20 (5) ◽  
pp. 895-899 ◽  
Author(s):  
Xueya Qian ◽  
Xiaowei Xi ◽  
Yubiao Jin
Keyword(s):  
Ovarian Carcinoma ◽  
Histological Grade ◽  
Clinical Stage ◽  
Disease Free Survival ◽  
Epithelial Ovarian Carcinoma ◽  
Poor Correlation ◽  
Advanced Clinical Stage ◽  
Free Survival ◽  
Disease Free ◽  
Lymphovascular Space Invasion

Introduction:To assess the prognostic value of lymphovascular space invasion (LVSI) in epithelial ovarian carcinoma.Methods:We reexamined single representative hematoxylin and eosin-stained sections of 66 patients with epithelial ovarian carcinoma to identify LVSI. A 4-grade system was used to classify LVSI: absent (no LVSI), mild (1-2 foci of LVSI), moderate (3-8 foci of LVSI), and severe (≥9 foci of LVSI). We investigated the possible associations between the grade of LVSI and clinicopathologic factors.Results:Lymphovascular space invasion was present in 36 patients (54.5%) and absent in 30 (45.5%). Statistical analysis indicated that LVSI was significantly associated with advanced clinical stage, poor histological grade, and lymph node metastasis. Follow-up studies indicated that the disease-free survival time for patients without LVSI was significantly longer than that for patients with moderate LVSI (P = 0.01) and severe LVSI (P = 0.001). The overall survival (OS) time for patients with moderate or severe LVSI was significantly shorter than that for patients with mild or no LVSI. The grade of LVSI was found to be significantly associated with OS (P = 0.004). The grade of LVSI showed poor correlation with disease-free survival and OS.Conclusions:The grade of LVSI is an important predictive factor for disease recurrence and poor survival of patients with epithelial ovarian carcinoma.

Sign in / Sign up

Export Citation Format

Share Document